CLINICAL IMMUNOBIOCHEMICAL MARKERS IN OPTIMIZING THE DIAGNOSTICS OF BRONCHIAL ASTHMA IN COMORBIDITY WITH TYPE 2 DIABETES MELLITUS. MAJMHS 2025, 1 (8), 51-63.